New study aims to tame Nintedanib's gut side effects in lung disease
NCT ID NCT06714812
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observes 100 adults with idiopathic pulmonary fibrosis (IPF) who are taking the drug nintedanib. The goal is to understand who is more likely to get diarrhea as a side effect and to see if lowering the dose helps. Researchers will track diarrhea severity and how dose changes affect patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS Azienda Ospedaliera-Universitaria di Bologna
Bologna, Bologna, 40138, Italy